Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111620 | 0.91 | ALDH1A1 (0.47) | ROCK2CYP3A4CYP2D6CYP2C9ROCK1 | |
| SCHEMBL11981825 | 0.90 | MAPT (0.37) | ROCK2CYP3A4CYP2D6CYP2C9ROCK1 | |
| SCHEMBL1111622 | 0.89 | GAA (0.41) | ROCK2CYP3A4CYP2D6CYP2C9ROCK1 | |
| SCHEMBL1111666 | 0.87 | HPGDS (0.59) | HPGDSHTR2CMCHR1 | |
| SCHEMBL1111640 | 0.85 | HPGDS (0.48) | HPGDS | |
| SCHEMBL7999504 | 0.80 | DDR2 (0.45) | ALDH1A1GAAMEN1KMT2AUSP2 | |
| SCHEMBL1111651 | 0.80 | ALDH1A1 (0.49) | ROCK2ROCK1ALDH1A1GAAMEN1 | |
| SCHEMBL12958860 | 0.80 | ALDH1A1 (0.48) | ALDH1A1GAAMEN1KMT2AUSP2 | |
| SCHEMBL1111610 | 0.79 | EPHX2 (0.49) | ALDH1A1GAAMEN1KMT2AUSP2 | |
| SCHEMBL7987320 | 0.78 | ITK (0.49) | CYP3A4CYP2C9ALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | claimed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | claimed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | claimed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | claimed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | CHRNA7, CHRNA5, CHRNA6 | ROCK2 2320/4885CYP3A4 3388/4885CYP2D6 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.